News
Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...
Wegovy® is indicated for chronic weight management in adults and adolescents (12+) with obesity or overweight and at least ...
22h
Money Talks News on MSNAre Your Weight-Loss Drugs Real? Novo Nordisk Sounds Alarm on KnockoffsOne in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a ...
In a recent panel conversation, healthcare and industry experts discussed where to find reliable guidance in a sea of ...
23h
Zacks.com on MSNCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.
A labeling mistake has led to a nationwide recall of four different types of Ritz peanut butter cracker sandwich cartons, ...
Explore more
Hims & Hers Health (HIMS) is quickly becoming one of the most compelling stories in the market as an emerging powerhouse in the direct-to-consumer healthcare space. The stock has posted outsized gains ...
On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of ...
BENGALURU] European shares closed lower on Friday (Jul 11), as losses in banks and healthcare stocks weighed at the end of a ...
13h
ABP News on MSNIndians Double Investments In US Stocks Despite Market Volatility: ReportThe April-June quarter was anything but ordinary for the US stock market, even as the S&P 500 plummeted 13 per cent in April ...
Wockhardt announces its exit from the US generics market, shifting focus to its innovative antibiotic and biologicals ...
Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results